Well, with Novartis on board and mind boggling revenues potential, CNAT is grossly overlooked and neglected by the market at this point. when P2b is announced, the picture will change.
this is what some funds do... they sell on spikes (also to have their year end performance look better), maybe they bought back at lower prices or maybe they think a 150% gain was enough for them. I am almost sure that most of the investors now who have bought under $5 will be lost during the multi year run up to $1,000+ . We also need the ones who sell and short the stock otherwise it would go up too quickly and we could not keep accumulating at such low prices
News 
Market Data 
Discover 
